Navigation Links
Pharmacyclics Reports Second Quarter 2014 Results
Date:7/31/2014

e opinion was based on data from the Phase II study (PCYC-1104) in MCL, a Phase III RESONATE™ study (PCYC-1112-CA) and a Phase II study (PCYC-1102) in CLL.

The EMA is a decentralized agency of the European Union responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the 28 countries of the European Union. The positive opinion of the EMA's CHMP will be reviewed by the European Commission, and a final decision on IMBRUVICA is anticipated later this year. In addition to European markets, a worldwide regulatory filing program for IMBRUVICA currently is underway.

Clinical UpdateIMBRUVICA (ibrutinib) clinical trials are active in all regions including US, Europe, Asia Pacific, Canada and Latin America. Currently IMBRUVICA is being developed in 8 different B-cell malignancies. There are 12 Phase III clinical trials initiated with IMBRUVICA and a total of 50 trials are registered on www.clinicaltrials.gov, of which 23 are investigating combination regimens while the remaining 27 are investigating IMBRUVICA monotherapy. The total planned enrollment for all of our clinical studies investigating IMBRUVICA is approximately 7,200 patients. As of today there are seven Phase III studies focused on patients with CLL, two designed for patients with MCL, one for patients with diffuse large B-cell lymphoma, one for patients with follicular lymphoma and one for Waldenstroms macroglobulinemia. To date, over 3,300 patients have been treated in Company-sponsored trials which are being conducted in over 35 countries around the globe and which involve more than 800 principal investigators.

During the second quarter, we initiated a Company-sponsored, randomized, double-blind, placebo-controlled, Phase III study of IMBRUVICA or placebo in combination with rituximab in previously treated Waldenstrom's Macroglobulinemia patients. The total planned enrollment for this study i
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014
2. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
3. WuXi PharmaTech to Partner with Pharmacyclics
4. Pharmacyclics Reports Third Quarter 2013 Results
5. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
6. Pharmacyclics Reports Second Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
8. Pharmacyclics Reports First Quarter 2013 Results
9. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
10. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
11. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... IRVINE, Calif. , July 30, 2015 /PRNewswire/ ... Novartis /Alcon executives have recently contacted the Company ... will begin as early as Monday, August 3, ... been quoted as saying that the coming electronic ... billions of dollars over the next several years.  ...
(Date:7/30/2015)... and VANCOUVER , July 30, 2015 ... today that it will report its second quarter 2015 ... will host a conference call and live webcast at ... financial results, clinical development programs and a general corporate ... on to the Investor Relations page of the OncoGenex ...
(Date:7/30/2015)... THOUSAND OAKS, Calif. , July 30, 2015  Amgen ... Fred Hassan , partner and managing director of Warburg Pincus ... "We are pleased to welcome Fred Hassan and ... to the Amgen Board," said Robert A. Bradway , ... expertise and commitment to innovation will serve Amgen well." ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3
... 10, 2011 Rapid Fire Marketing (Pink Sheets: ... subsidiary company, Medical Cannabis Management (MCM) is taking ... Currently, MCM provides marketing, consulting and management services and has ... growing of medical cannabis. Now MCM is looking to expand ...
... In an on-going effort to give back to the local ... the company will donate $5,200 to the Greater Boston Food ... card issued to loyal conference attendees in November of 2010, ... a future conference of choice. This year, in the spirit ...
Cached Medicine Technology:Rapid Fire Marketing's Medical Cannabis Management Looking to Expand Business 2The Center for Business Intelligence Donates More than $5,000 to the Greater Boston Food Bank 2
(Date:7/31/2015)... ... July 31, 2015 , ... ... wide variety of nutritional and wellness products, announced the addition of Vincent Aquilino ... massage therapy, active isolated stretching and the prevention and rehabilitation of injuries, has ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... with the recent implementation of Microsoft Dynamics GP for a senior living facility ... is now supporting senior living communities in 16 states. This further expansion was ...
(Date:7/31/2015)... ... July 31, 2015 , ... With ... growing number of individuals who remain undiagnosed, treatment options for patients are becoming ... from traditional CPAP therapy due to its overall lack of comfort and highly ...
(Date:7/30/2015)... Church, VA (PRWEB) , ... July 31, 2015 ... ... Manufacturing Floor:, Reduce Errors By 50% or More, **Presented by FDAnews and Ginette ... Dr. Ginette Collazo, a 15 year veteran of helping drug, biologic and device ...
(Date:7/30/2015)... ... 2015 , ... Committed to helping the next generation succeed - Mercy College ... to the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues a call ... the support they need to think more broadly about their future. Building on what ...
Breaking Medicine News(10 mins):Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3
... Ariz., Nov. 6 The Providence Service,Corporation (Nasdaq: ... of $70 million of Convertible Senior Subordinated Notes due ... Placement Agent for the,transaction. The private placement was ... interest at 6.5% per annum and are convertible into,Providence ...
... In recognition of,Alzheimer,s Awareness Month, The HealthCentral ... special,feature to encourage early detection and a ... those who suffer from the condition or,are ... disease., The special Alzheimer,s Awareness online ...
... Health Advisory Council,Appointed to AARP State Leadership Team, ... the appointment of Ruby Haughton-Pitts, to its State ... be a member,of the organization,s seven-member leadership committee, ... of health care access for low-income Americans,Haughton-Pitts was ...
... The Disabled American,Veterans (DAV) is commending lawmakers ... largest increase in funding for the Department of,Veterans ... Congress and the,Administration to support this important legislation ... Construction and Veterans Affairs Appropriations bill,calls for an ...
... SANTA MONICA, Calif., Nov. 6 The scant,details of ... Fabian Nunez and Senate President pro Tem Don Perata ... families but would,guarantee a windfall for private health insurance ... taxpayers, according to the Foundation for,Taxpayer and Consumer Rights ...
... and advanced liver disease who did not respond ... their liver enzymes, viral levels, and liver inflammation ... treatment did not slow or prevent the progression ... the clinical trial, Hepatitis C Antiviral Long-Term Treatment ...
Cached Medicine News:Health News:Providence Service Corporation Completes Private Placement of $70 Million of Convertible Senior Subordinated Notes 2Health News:The HealthCentral Network Honors Alzheimer's Awareness Month 2Health News:Haughton-Pitts Joins AARP Illinois Executive Council 2Health News:VA Budget Earns High Praise 2Health News:The Good, the Bad, and the Ugly of the Nunez/Perata Health Plan 2Health News:Hepatitis C treatment reduces the virus but serious liver problems may progress 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: